Liver Cancer - Pipeline Review, H1 2016

  • ID: 3783300
  • Report
  • 1073 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4SC AG
  • CASI Pharmaceuticals Inc.
  • Genoscience Pharma
  • Johnson & Johnson
  • NormOxys, Inc.
  • Regulus Therapeutics Inc.
  • MORE
Liver Cancer - Pipeline Review, H1 2016

Summary

‘Liver Cancer - Pipeline Review, H1 2016’, provides an overview of the Liver Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Liver Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Liver Cancer and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Liver Cancer
- The report reviews pipeline therapeutics for Liver Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Liver Cancer therapeutics and enlists all their major and minor projects
- The report assesses Liver Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Liver Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Liver Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Liver Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4SC AG
  • CASI Pharmaceuticals Inc.
  • Genoscience Pharma
  • Johnson & Johnson
  • NormOxys, Inc.
  • Regulus Therapeutics Inc.
  • MORE
Introduction

Liver Cancer Overview

Therapeutics Development

Liver Cancer - Therapeutics under Development by Companies

Liver Cancer - Therapeutics under Investigation by Universities/Institutes

Liver Cancer - Pipeline Products Glance

Liver Cancer - Products under Development by Companies

Liver Cancer - Products under Investigation by Universities/Institutes

Liver Cancer - Companies Involved in Therapeutics Development

Liver Cancer - Therapeutics Assessment

Drug Profiles

Liver Cancer - Dormant Projects

Liver Cancer - Discontinued Products

Liver Cancer - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Liver Cancer, H1 2016

Number of Products under Development for Liver Cancer - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Development by Companies, H1 2016 (Contd..3)

Number of Products under Development by Companies, H1 2016 (Contd..4)

Number of Products under Development by Companies, H1 2016 (Contd..5)

Number of Products under Development by Companies, H1 2016 (Contd..6)

Number of Products under Development by Companies, H1 2016 (Contd..7)

Number of Products under Development by Companies, H1 2016 (Contd..8)

Number of Products under Development by Companies, H1 2016 (Contd..9)

Number of Products under Development by Companies, H1 2016 (Contd..10)

Number of Products under Development by Companies, H1 2016 (Contd..11)

Number of Products under Development by Companies, H1 2016 (Contd..12)

Number of Products under Investigation by Universities/Institutes, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Development by Companies, H1 2016 (Contd..4)

Products under Development by Companies, H1 2016 (Contd..5)

Products under Development by Companies, H1 2016 (Contd..6)

Products under Development by Companies, H1 2016 (Contd..7)

Products under Development by Companies, H1 2016 (Contd..8)

Products under Development by Companies, H1 2016 (Contd..9)

Products under Development by Companies, H1 2016 (Contd..10)

Products under Development by Companies, H1 2016 (Contd..11)

Products under Development by Companies, H1 2016 (Contd..12)

Products under Development by Companies, H1 2016 (Contd..13)

Products under Development by Companies, H1 2016 (Contd..14)

Products under Development by Companies, H1 2016 (Contd..15)

Products under Development by Companies, H1 2016 (Contd..16)

Products under Development by Companies, H1 2016 (Contd..17)

Products under Development by Companies, H1 2016 (Contd..18)

Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)

Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)

Liver Cancer - Pipeline by 4SC AG, H1 2016

Liver Cancer - Pipeline by AB Science SA, H1 2016

Liver Cancer - Pipeline by Acceleron Pharma, Inc., H1 2016

Liver Cancer - Pipeline by ACROVIS Pharma AG, H1 2016

Liver Cancer - Pipeline by Adaptimmune Therapeutics Plc, H1 2016

Liver Cancer - Pipeline by Aduro BioTech, Inc., H1 2016

Liver Cancer - Pipeline by Advanced Accelerator Applications S.A., H1 2016

Liver Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016

Liver Cancer - Pipeline by Alfact Innovation, H1 2016

Liver Cancer - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016

Liver Cancer - Pipeline by American Gene Technologies International Inc., H1 2016

Liver Cancer - Pipeline by Amgen Inc., H1 2016

Liver Cancer - Pipeline by AndroScience Corporation, H1 2016

Liver Cancer - Pipeline by APAvadis Biotechnologies Srl, H1 2016

Liver Cancer - Pipeline by Arbutus Biopharma Corporation, H1 2016

Liver Cancer - Pipeline by ArQule, Inc., H1 2016

Liver Cancer - Pipeline by Array BioPharma Inc., H1 2016

Liver Cancer - Pipeline by Arrowhead Pharmaceuticals, Inc., H1 2016

Liver Cancer - Pipeline by Astex Pharmaceuticals, Inc., H1 2016

Liver Cancer - Pipeline by AstraZeneca Plc, H1 2016

Liver Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016

Liver Cancer - Pipeline by Bayer AG, H1 2016

Liver Cancer - Pipeline by Beijing Kawin Technology Share-Holding Co., Ltd., H1 2016

Liver Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H1 2016

Liver Cancer - Pipeline by Bio-Cancer Treatment International Limited, H1 2016

Liver Cancer - Pipeline by BioCancell Ltd, H1 2016

Liver Cancer - Pipeline by Biogazelle, H1 2016

Liver Cancer - Pipeline by Biomics Biotechnologies Co., Ltd., H1 2016

Liver Cancer - Pipeline by Bioneer Corporation, H1 2016

Liver Cancer - Pipeline by BioStar Pharmaceuticals, Inc., H1 2016

Liver Cancer - Pipeline by Blueprint Medicines Corporation, H1 2016

Liver Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016

Liver Cancer - Pipeline by Boston Biomedical, Inc., H1 2016

Liver Cancer - Pipeline by Can-Fite BioPharma Ltd., H1 2016

Liver Cancer - Pipeline by CASI Pharmaceuticals Inc., H1 2016

Liver Cancer - Pipeline by CCRP Therapeutics GmbH, H1 2016

Liver Cancer - Pipeline by Celgene Corporation, H1 2016

Liver Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016

Liver Cancer - Pipeline by Celprogen, Inc., H1 2016

Liver Cancer - Pipeline by Celsion Corporation, H1 2016

Liver Cancer - Pipeline by China Medical System Holdings Limited, H1 2016

Liver Cancer - Pipeline by Chiome Bioscience, Inc., H1 2016

Liver Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2016

Liver Cancer - Pipeline by Chroma Therapeutics Limited, H1 2016

Liver Cancer - Pipeline by CohBar, Inc., H1 2016

Liver Cancer - Pipeline by CytRx Corporation, H1 2016

Liver Cancer - Pipeline by CZ BioMed Corp, H1 2016

Liver Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2016

Liver Cancer - Pipeline by Delcath Systems, Inc., H1 2016

Liver Cancer - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016

Liver Cancer - Pipeline by Digna Biotech, S.L., H1 2016

Liver Cancer - Pipeline by Double Bond Pharmaceutical International AB, H1 2016

Liver Cancer - Pipeline by Eisai Co., Ltd., H1 2016

Liver Cancer - Pipeline by Eli Lilly and Company, H1 2016

Liver Cancer - Pipeline by Endocyte, Inc., H1 2016

Liver Cancer - Pipeline by eTheRNA Immunotherapies NV, H1 2016

Liver Cancer - Pipeline by Eureka Therapeutics, Inc., H1 2016

Liver Cancer - Pipeline by Exelixis, Inc., H1 2016

Liver Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Liver Cancer - Pipeline by Genelux Corporation, H1 2016

Liver Cancer - Pipeline by Genoscience Pharma, H1 2016

Liver Cancer - Pipeline by Genosco, H1 2016

Liver Cancer - Pipeline by GenSpera, Inc., H1 2016

Liver Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016

Liver Cancer - Pipeline by Golden Biotechnology Corp., H1 2016

Liver Cancer - Pipeline by Green Cross Cell Corporation, H1 2016

Liver Cancer - Pipeline by H3 Biomedicine Inc., H1 2016

Liver Cancer - Pipeline by HanAll Biopharma Co., Ltd., H1 2016

Liver Cancer - Pipeline by HEC Pharm Co., Ltd., H1 2016

Liver Cancer - Pipeline by HitGen LTD, H1 2016

Liver Cancer - Pipeline by Horizon Pharma Plc, H1 2016

Liver Cancer - Pipeline by Huperion Sarl, H1 2016

Liver Cancer - Pipeline by Immunicum AB, H1 2016

Liver Cancer - Pipeline by Immunitor, Inc., H1 2016

Liver Cancer - Pipeline by Immunomedics, Inc., H1 2016

Liver Cancer - Pipeline by Immunovative Therapies, Ltd., H1 2016

Liver Cancer - Pipeline by IMPACT Therapeutics, Inc., H1 2016

Liver Cancer - Pipeline by In-Cell-Art S.A.S., H1 2016

Liver Cancer - Pipeline by Incanthera Ltd., H1 2016

Liver Cancer - Pipeline by Incuron, LLC, H1 2016

Liver Cancer - Pipeline by InteRNA Technologies B.V., H1 2016

Liver Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H1 2016

Liver Cancer - Pipeline by Jenrin Discovery, Inc., H1 2016

Liver Cancer - Pipeline by Johnson & Johnson, H1 2016

Liver Cancer - Pipeline by JW Pharmaceutical Corporation, H1 2016

Liver Cancer - Pipeline by KAHR medical Ltd., H1 2016

Liver Cancer - Pipeline by Karcinolys SAS, H1 2016

Liver Cancer - Pipeline by Keystone Nano, Inc., H1 2016

Liver Cancer - Pipeline by Kite Pharma, Inc., H1 2016

Liver Cancer - Pipeline by Komipharm International Co., Ltd., H1 2016

Liver Cancer - Pipeline by Kowa Company, Ltd., H1 2016

Liver Cancer - Pipeline by Les Laboratoires Servier SAS, H1 2016

Liver Cancer - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016

Liver Cancer - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2016

Liver Cancer - Pipeline by Lytix Biopharma AS, H1 2016

Liver Cancer - Pipeline by MaxCyte, Inc., H1 2016

Liver Cancer - Pipeline by MedImmune, LLC, H1 2016

Liver Cancer - Pipeline by Medivation, Inc., H1 2016

Liver Cancer - Pipeline by Medivir AB, H1 2016

Liver Cancer - Pipeline by Merck & Co., Inc., H1 2016

Liver Cancer - Pipeline by Merck KGaA, H1 2016

Liver Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016

Liver Cancer - Pipeline by Midatech Pharma Plc, H1 2016

Liver Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016

Liver Cancer - Pipeline by Mirna Therapeutics, Inc., H1 2016

Liver Cancer - Pipeline by Molecular Partners AG, H1 2016

Liver Cancer - Pipeline by MolMed S.p.A., H1 2016

Liver Cancer - Pipeline by MultiCell Technologies, Inc., H1 2016

Liver Cancer - Pipeline by Nimbus Therapeutics, LLC, H1 2016

Liver Cancer - Pipeline by NormOxys, Inc., H1 2016

Liver Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2016

Liver Cancer - Pipeline by Novartis AG, H1 2016

Liver Cancer - Pipeline by NovaTarg Therapeutics, Inc, H1 2016

Liver Cancer - Pipeline by Nymox Pharmaceutical Corporation, H1 2016

Liver Cancer - Pipeline by Omeros Corporation, H1 2016

Liver Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2016

Liver Cancer - Pipeline by Oncolys BioPharma Inc., H1 2016

Liver Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016

Liver Cancer - Pipeline by OncoTherapy Science, Inc., H1 2016

Liver Cancer - Pipeline by Oneness Biotech Co., Ltd., H1 2016

Liver Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016

Liver Cancer - Pipeline by Onxeo SA, H1 2016

Liver Cancer - Pipeline by OPKO Health, Inc., H1 2016

Liver Cancer - Pipeline by Oribase Pharma, H1 2016

Liver Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2016

Liver Cancer - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016

Liver Cancer - Pipeline by Peptinov SAS, H1 2016

Liver Cancer - Pipeline by Pfizer Inc., H1 2016

Liver Cancer - Pipeline by Pharma Mar, S.A., H1 2016

Liver Cancer - Pipeline by PharmAbcine, Inc., H1 2016

Liver Cancer - Pipeline by PharmaEssentia Corporation, H1 2016

Liver Cancer - Pipeline by Phosplatin Therapeutics LLC, H1 2016

Liver Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016

Liver Cancer - Pipeline by Progen Pharmaceuticals Limited, H1 2016

Liver Cancer - Pipeline by ProMetic Life Sciences Inc., H1 2016

Liver Cancer - Pipeline by Provecs Medical GmbH, H1 2016

Liver Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016

Liver Cancer - Pipeline by Quimatryx, S.L., H1 2016

Liver Cancer - Pipeline by Raptor Pharmaceutical Corp., H1 2016

Liver Cancer - Pipeline by RedHill Biopharma Ltd., H1 2016

Liver Cancer - Pipeline by Regen BioPharma, Inc., H1 2016

Liver Cancer - Pipeline by Regulus Therapeutics Inc., H1 2016

Liver Cancer - Pipeline by Rigontec GmbH, H1 2016

Liver Cancer - Pipeline by Saronic Biotechnology, Inc., H1 2016

Liver Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016

Liver Cancer - Pipeline by Shenogen Pharma Group Ltd., H1 2016

Liver Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016

Liver Cancer - Pipeline by Silence Therapeutics Plc, H1 2016

Liver Cancer - Pipeline by Sillajen Biotherapeutics, H1 2016

Liver Cancer - Pipeline by Simcere Pharmaceutical Group, H1 2016

Liver Cancer - Pipeline by Synovo GmbH, H1 2016

Liver Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016

Liver Cancer - Pipeline by Tara Immuno-Oncology Therapeutics LLC, H1 2016

Liver Cancer - Pipeline by Targetome, H1 2016

Liver Cancer - Pipeline by Therapure Biopharma Inc., H1 2016

Liver Cancer - Pipeline by Theravectys SA, H1 2016

Liver Cancer - Pipeline by Tiziana Life Sciences Plc, H1 2016

Liver Cancer - Pipeline by Toko Pharmaceutical Industries Co., Ltd., H1 2016

Liver Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016

Liver Cancer - Pipeline by Transgene Biotek Limited, H1 2016

Liver Cancer - Pipeline by Tumorend, LLC, H1 2016

Liver Cancer - Pipeline by UbiVac, LLC, H1 2016

Liver Cancer - Pipeline by VasGene Therapeutics, Inc., H1 2016

Liver Cancer - Pipeline by Vaxon Biotech, H1 2016

Liver Cancer - Pipeline by Vect-Horus S.A.S., H1 2016

Liver Cancer - Pipeline by Verlyx Pharma Inc., H1 2016

Liver Cancer - Pipeline by VG Life Sciences, Inc., H1 2016

Liver Cancer - Pipeline by Vicus Therapeutics, LLC, H1 2016

Liver Cancer - Pipeline by Virttu Biologics Limited, H1 2016

Liver Cancer - Pipeline by Vyriad, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Liver Cancer - Dormant Projects, H1 2016

Liver Cancer - Dormant Projects (Contd..1), H1 2016

Liver Cancer - Dormant Projects (Contd..2), H1 2016

Liver Cancer - Dormant Projects (Contd..3), H1 2016

Liver Cancer - Dormant Projects (Contd..4), H1 2016

Liver Cancer - Dormant Projects (Contd..5), H1 2016

Liver Cancer - Dormant Projects (Contd..6), H1 2016

Liver Cancer - Dormant Projects (Contd..7), H1 2016

Liver Cancer - Dormant Projects (Contd..8), H1 2016

Liver Cancer - Dormant Projects (Contd..9), H1 2016

Liver Cancer - Dormant Projects (Contd..10), H1 2016

Liver Cancer - Dormant Projects (Contd..11), H1 2016

Liver Cancer - Dormant Projects (Contd..12), H1 2016

Liver Cancer - Dormant Projects (Contd..13), H1 2016

Liver Cancer - Dormant Projects (Contd..14), H1 2016

Liver Cancer - Dormant Projects (Contd..15), H1 2016

Liver Cancer - Dormant Projects (Contd..16), H1 2016

Liver Cancer - Dormant Projects (Contd..17), H1 2016

Liver Cancer - Discontinued Products, H1 2016

Liver Cancer - Discontinued Products (Contd..1), H1 2016

Liver Cancer - Discontinued Products (Contd..2), H1 2016

Liver Cancer - Discontinued Products (Contd..3), H1 2016

List of Figures

Number of Products under Development for Liver Cancer, H1 2016

Number of Products under Development for Liver Cancer - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Assessment by Combination Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Top 10 Routes of Administration, H1 2016

Number of Products by Stage and Top 10 Routes of Administration, H1 2016

Number of Products by Top 10 Molecule Types, H1 2016

Number of Products by Stage and Top 10 Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 4SC AG
  • CASI Pharmaceuticals Inc.
  • Genoscience Pharma
  • Johnson & Johnson
  • NormOxys, Inc.
  • Regulus Therapeutics Inc.
  • MORE
Liver Cancer Liver cancer starts in the liver. The risk factors for liver cancer include hepatitis, cirrhosis, or scarring of liver, being male and having low weight at birth. Symptoms include a lump or pain on the right side of the abdomen and yellowing of the skin. Treatment of liver cancer may include chemotherapy, radiation and surgery.

Liver Cancer pipeline therapeutics constitutes close to 313 molecules. Out of which approximately 265 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 18, 63, 48, 4, 113 and 19 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 8, 7, 1, 29 and 3 molecules, respectively.

Our latest report Liver Cancer – Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Liver Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Liver Cancer and features dormant and discontinued projects.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 5
4SC AG
AB Science SA
Acceleron Pharma, Inc.
ACROVIS Pharma AG
Adaptimmune Therapeutics Plc
Aduro BioTech, Inc.
Advanced Accelerator Applications S.A.
Advenchen Laboratories, LLC
Alfact Innovation
Alnylam Pharmaceuticals, Inc.
American Gene Technologies International Inc.
Amgen Inc.
AndroScience Corporation
APAvadis Biotechnologies Srl
Arbutus Biopharma Corporation
ArQule, Inc.
Array BioPharma Inc.
Arrowhead Pharmaceuticals, Inc.
Astex Pharmaceuticals, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Bayer AG
Beijing Kawin Technology Share-Holding Co., Ltd.
Betta Pharmaceuticals Co. Ltd.
Bio-Cancer Treatment International Limited
BioCancell Ltd
Biogazelle
Biomics Biotechnologies Co., Ltd.
Bioneer Corporation
BioStar Pharmaceuticals, Inc.
Blueprint Medicines Corporation
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Can-Fite BioPharma Ltd.
CASI Pharmaceuticals Inc.
CCRP Therapeutics GmbH
Celgene Corporation
Celldex Therapeutics, Inc.
Celprogen, Inc.
Celsion Corporation
China Medical System Holdings Limited
Chiome Bioscience, Inc.
Chipscreen Biosciences Ltd
Chroma Therapeutics Limited
CohBar, Inc.
CytRx Corporation
CZ BioMed Corp
Daiichi Sankyo Company, Limited
Delcath Systems, Inc.
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
Double Bond Pharmaceutical International AB
Eisai Co., Ltd.
Eli Lilly and Company
Endocyte, Inc.
eTheRNA Immunotherapies NV
Eureka Therapeutics, Inc.
Exelixis, Inc.
F. Hoffmann-La Roche Ltd.
Genelux Corporation
Genoscience Pharma
Genosco
GenSpera, Inc.
GlaxoSmithKline Plc
Golden Biotechnology Corp.
Green Cross Cell Corporation
H3 Biomedicine Inc.
HanAll Biopharma Co., Ltd.
HEC Pharm Co., Ltd.
HitGen LTD
Horizon Pharma Plc
Huperion Sarl
Immunicum AB
Immunitor, Inc.
Immunomedics, Inc.
Immunovative Therapies, Ltd.
IMPACT Therapeutics, Inc.
In-Cell-Art S.A.S.
Incanthera Ltd.
Incuron, LLC
InteRNA Technologies B.V.
Jasco Pharmaceuticals, LLC.
Jenrin Discovery, Inc.
Johnson & Johnson
JW Pharmaceutical Corporation
KAHR medical Ltd.
Karcinolys SAS
Keystone Nano, Inc.
Kite Pharma, Inc.
Komipharm International Co., Ltd.
Kowa Company, Ltd.
Les Laboratoires Servier SAS
Ligand Pharmaceuticals, Inc.
Lixte Biotechnology Holdings, Inc.
Lytix Biopharma AS
MaxCyte, Inc.
MedImmune, LLC
Medivation, Inc.
Medivir AB
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Midatech Pharma Plc
Millennium Pharmaceuticals, Inc.
Mirna Therapeutics, Inc.
Molecular Partners AG
MolMed S.p.A.
MultiCell Technologies, Inc.
Nimbus Therapeutics, LLC
NormOxys, Inc.
Northwest Biotherapeutics, Inc.
Novartis AG
NovaTarg Therapeutics, Inc
Nymox Pharmaceutical Corporation
Omeros Corporation
Omnitura Therapeutics Inc.
Oncolys BioPharma Inc.
OncoMed Pharmaceuticals, Inc.
OncoTherapy Science, Inc.
Oneness Biotech Co., Ltd.
Ono Pharmaceutical Co., Ltd.
Onxeo SA
OPKO Health, Inc.
Oribase Pharma
Otsuka Holdings Co., Ltd.
Panacea Pharmaceuticals, Inc.
Peptinov SAS
Pfizer Inc.
Pharma Mar, S.A.
PharmAbcine, Inc.
PharmaEssentia Corporation
Phosplatin Therapeutics LLC
Polaris Pharmaceuticals, Inc.
Progen Pharmaceuticals Limited
ProMetic Life Sciences Inc.
Provecs Medical GmbH
Provectus Biopharmaceuticals, Inc.
Quimatryx, S.L.
Raptor Pharmaceutical Corp.
RedHill Biopharma Ltd.
Regen BioPharma, Inc.
Regulus Therapeutics Inc.
Rigontec GmbH
Saronic Biotechnology, Inc.
Savoy Pharmaceuticals, Inc.
Shenogen Pharma Group Ltd.
Shenzen SiBiono GeneTech Co., Ltd.
Silence Therapeutics Plc
Sillajen Biotherapeutics
Simcere Pharmaceutical Group
Synovo GmbH
Taiwan Liposome Company, Ltd.
Tara Immuno-Oncology Therapeutics LLC
Targetome
Therapure Biopharma Inc.
Theravectys SA
Tiziana Life Sciences Plc
Toko Pharmaceutical Industries Co., Ltd.
TRACON Pharmaceuticals, Inc.
Transgene Biotek Limited
Tumorend, LLC
UbiVac, LLC
VasGene Therapeutics, Inc.
Vaxon Biotech
Vect-Horus S.A.S.
Verlyx Pharma Inc.
VG Life Sciences, Inc.
Vicus Therapeutics, LLC
Virttu Biologics Limited
Vyriad
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll